Fenbendazole acts as a moderate microtubule destabilizing agent and causes cancer cell death by modulating multiple cellular pathways (2018)

Peer-Reviewed Study · N. Dogra, A. Kumar, T. Mukhopadhyay · August 9, 2018

N. Dogra et al., 2018-08-09: Indian laboratory study reporting that fenbendazole destabilises microtubules, inhibits glucose uptake and hexokinase II, and slows growth of A549 human lung-cancer xenografts in nude mice given the drug orally.

It blocked the growth of human xenografts in nu/nu mice model when mice were fed with the drug orally. The results, in conjunction with our earlier data, suggest that FZ is a new microtubule interfering agent that displays anti-neoplastic activity

p.1 (abstract)

N. Dogra et al., 2018-08-09: Indian laboratory study reporting that fenbendazole destabilises microtubules, inhibits glucose uptake and hexokinase II, and slows growth of A549 human lung-cancer xenografts in nude mice given the drug orally. Study type: cell-line plus mouse xenograft study. Cells: A549 and other human cancer lines; female athymic nu/nu mice bearing A549 xenografts (animal number not stated in abstract). Country: India (ACTREC, Navi Mumbai). Dose/route/schedule in vivo: 1 mg per mouse orally every second day for 12 days. Comparator: mock-treated controls. Funder: no funding statement found in the PMC text; only an acknowledgement to Dr Rita Mulherkar (ACTREC) for assistance with nude-mouse experiments. Conflicts: 'The authors declare no competing interests.' Drug maker: not named; fenbendazole used as laboratory reagent. Cell-culture and mouse data only – no human dosing, no pharmacokinetics. Also filed as FBC-13 (claims C3, C6). Study type: animal.